180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, has closed on its previously announced issuance and sale of 1,570,680 shares of the company’s common stock in a registered direct offering and warrants. The shares were offered at a purchase price of $1.91 in a concurrent private placement, resulting in gross proceeds of an estimated $3 million. According to the announcement, the private placement warrants have an exercise price of $1.78 per share, are immediately exercisable, and will expire five and one-half years from the date of issuance. ATNF anticipates using the offering funds for research and development expenses as well as general corporate purposes. A.G.P./Alliance Global Partners acted as the sole placement agent for the offering.
To view the full press release, visit https://ibn.fm/7Y8E2
About 180 Life Sciences Corp.
180 Life Sciences is a clinical-stage biotechnology company driving groundbreaking studies into clinical programs that are seeking to address major unmet medical needs. The company’s focus is a novel program to treat several inflammatory disorders using anti-TNF (tumor necrosis factor). For more information about the company, visit www.180LifeSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at https://ibn.fm/ATNF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork
